210,000
-0.47%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Celltrion
Its shares trade on KRX under the ticker 068270.KS. It has been listed since 19 July 2005. In the fiscal year to 31 December 2025, it reported revenue of â‚©4.16trn and net income of â‚©1.03trn. At that date it held total assets of â‚©22.33trn and shareholders' equity of â‚©17.21trn.
Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. The company is headquartered in Incheon, Incheon. The company went IPO on 2005-07-19. The firm operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The firm's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The firm sells its products in domestic and overseas markets such as Europe and the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 19 Jul 2005
- Employees
- 1,074
- Website
- celltrion.com ↗
Leadership
Pay as last reported
- Mr. Jeong Jin SeoChairman, since 2008â‚©1.23bn
- Mr. Jeong Won YoonPresident
- Mr. Wu Seong GiCo-Chief Executive Officer, Vice Chairman, since 2008â‚©1.77bn
- Mr. Hyeong Gi KimCo-Chief Executive Officer, Director, since 2008
- Mr. Jin Seok SeoCo-Chief Executive Officer, Directorâ‚©1.75bn
- Mr. Jeong Su SeoVice Chairman, since 2024
- Mr. Jun Seok SeoSenior Vice Chairman
- Mr. Sang Jun LeeSenior Vice President, since 2018â‚©579.0m
- Mr. Min Cheol ShinVice President, since 2021â‚©556.0m
- Mr. Gi Seong GwonVice President, since 2023â‚©704.0m
- Mr. Yun Mo GuManaging Director
- Mr. Ho Wung KimManaging Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 77
- Environment
- 73
- Social
- 99
- Governance
- 57
- Direct emissions (scope 1)
- 22,457 t
- Energy emissions (scope 2)
- 42,260 t
- Value chain emissions (scope 3)
- 28,798 t
- Women in the workforce
- 42%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Celltrion Inc has a strong portfolio of innovative, high-quality biopharmaceutical products.
- The company has a robust research and development division, investing in cutting-edge technologies to fuel future growth.
- Celltrion Inc has established strong partnerships with global pharmaceutical companies, enabling it to expand its market reach.
Weaknesses
- Celltrion Inc faces the challenge of increasing competition, with other companies also focusing on the biopharmaceutical sector.
- The company heavily relies on a limited number of key products, making it vulnerable to potential market fluctuations.
- Celltrion Inc's manufacturing processes are complex, requiring consistent quality control measures to maintain product efficacy.
Opportunities
- The growing global demand for biologics provides Celltrion Inc with opportunities to expand its market presence.
- The company can leverage its expertise in biosimilar development to enter emerging markets and capture untapped potential.
- Celltrion Inc can explore strategic collaborations and licensing deals to further enhance its product pipeline and market opportunities.
Threats
- Regulatory challenges and changing governmental policies regarding biopharmaceuticals can pose threats to Celltrion Inc's operations.
- Intense competition from both established pharmaceutical companies and emerging biotech firms may impact the company's market share.
- Economic fluctuations and global macroeconomic factors can impact demand for Celltrion Inc's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.